Feature | Heart Valve Technology | March 23, 2017

TAVR Can Cause Silent Cerebral Microbleeds, Neurological Impairment

Microbleeds after endovascular procedures could harm thinking, memory for some patients

microbleeds, brain bleeds caused by TAVR

An MRI brain scan showing multiple microbleeds in a transcatheter aortic valve replacement (TAVR) patient from the study.

March 22, 2017 — A quarter of the patients in a single-center study of 84 patients undergoing transcatheter aortic valve replacement (TAVR) developed new cerebral microbleeds. The late-breaking study was presented at the at the American College of Cardiology (ACC) 2017 meeting. 

Reseachers said brain microbleeds increase with age and are associated with cognitive decline, but there was concern TAVR might increase in incidence of these bleeds. The study used magnetic resonance imaging (MRI) scans of the brain and cognitive tests to determine the impact of TAVR.

Previous studies of MRI scans in patients age 80 and older have shown evidence of microbleeds in up to 30 percent of elderly patients. This study revealed increased risks of microbleeding among patients who had undergone a previous cardiovascular intervention and among those with more prolonged exposure to anticoagulant medications, which are used to prevent blood clots that cause strokes and mini-strokes in patients undergoing cardiac procedures. It is the first study to link microbleeding with TAVR and the first to investigate microbleeding as a side effect of any cardiac procedure. 

“We are all aware of the potential for silent ischemic strokes [mini strokes] after these endovascular procedures, but our study points to the opposite risk — microbleeding — that we have not previously been aware of,” said Eric Van Belle, M.D., Ph.D., a cardiologist at the Centre Hospitalier Regional in Lille, France and the study’s lead author. “With more and more endovascular procedures, which require anticoagulants, it could be that these procedures are one of the main triggers of microbleeding seen in the older population. It raises the concern that we may be increasing the risk of this microbleeding with each intervention we perform.” 

To shed light on microbleeds and their possible connection to endovascular procedures such as TAVR or anticoagulant use associated with these procedures, researchers performed MRI scans and questionnairebased neurological tests in 84 patients before and after the patients underwent TAVR at Centre Hospitalier Regional in Lille, France. Patients underwent MRI scans one day before TAVR and three days after TAVR. Questionnaire-based neurological tests were conducted prior to TAVR, followed by three days after and six months after the procedure. 

TAVR is a procedure to replace a patient’s faulty aortic valve with an artificial valve. Clinicians thread the new valve to the heart through a catheter in the groin or chest. TAVR is generally used for patients in whom open-heart surgery poses an intermediate to high risk, which typically includes older patients and those who have multiple health problems. 

Before TAVR, MRI scans revealed at least one microbleed in 26 percent of patients. At three days after the procedure, a total of 40 percent of patients had microbleeds and 23 percent had new microbleeds that were not present before TAVR. 

Microbleeds observed both before and after TAVR were associated with deficiencies in thinking and memory in the questionnaire-based neurocognitive assessments. Factors that were associated with a significantly higher risk of microbleeds included having a previous cardiovascular intervention, prolonged exposure to anticoagulation, history of bleeding, longer exposure to fluoroscopy during TAVR, and balloon post-dilation, a procedure sometimes used in conjunction with TAVR to reduce leakage of blood across the new valve. 

Van Belle said the results strongly suggest that further research is needed to elucidate the causes of microbleeds and determine whether changes in anticoagulation management can help to reduce the risk. He said that the results suggest systematic MRI investigation should be conducted in studies investigating new anticoagulation regimen for patients undergoing TAVR. Currently, he said, MRI scans of the brain are rarely used to assess safety outcomes in cardiovascular studies, in part because MRI cannot be used in patients with a pacemaker or other types of implanted devices. 

“It is difficult to do this kind of MRI study in this older population, but based on our results I would say that it is worth it to do so when investigating a new treatment or treatment modification,” Van Belle said. “Both mini-strokes and microbleeds likely play a role in cognitive decline. It is possible that using too much anticoagulation therapy could be as bad as using too little.” 

The study was limited primarily by its small size. In addition, it was not able to definitively show whether new microbleeds observed after TAVR were actually caused by TAVR, the use of anticoagulants or other factors. Further research could be conducted to include a larger study population, involve younger patients or potentially investigate microbleeding after surgical aortic valve replacement or other cardiac procedures, Van Belle said.

Read the related article from another ACC.17 late-breaker concerning TAVR valve leaflet thrombosis “CT Scans Reveal Reduced Leaflet Motion After Aortic Valve Replacement.”
 

 

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init